Role of Vitamic C and E in high blood pressure during pregnancy

Phase 3

Recruiting

Brief Summary: Pregnant women at high risk for developing preeclampsia will be randomized to receive Vitc (1000 mg) and Vit E (400 IU) or placebo (crystalline dextrose). Women will be watched for development of preeclampsia, maternal and fetal complications. Additionally, echocardiographic parameters will be obtained to find the effect of antioxidant on systolic and diastolic function.

Recruitment & Eligibility

Inclusion Criteria

Inclusion criteria: Pregnant women presenting in antenatal clinic of JIPMR between 14- 22 weeks of gestation with one or more risks factors a.
preeclampsia/eclampsia in previous pregnancy, b.
chronic hypertension, c.
renal disease, d.
HELLP syndrome in prior pregnancy, e.
pregestational diabetes, f.
women with BMI 30 kg/m2, g.
antiphospholipid syndromes, h.
multifetal pregnancy, i.
thrombophilia, j.
Assisted reproductive technique conception, k.
age more than 35 years.

Exclusion Criteria

Exclusion criteria: 1.
Pregnant women less than 18 years 2.
Women with known cardiac lesion 3.
Women with known chronic respiratory disease (Tuberculosis, COPD, Bronchial asthma) 4.Women receiving warfarin therapy 5.Women unable to give informed consent.

Primary Outcome Measures

Name	Time	Method
Primary outcome measure includes incidence of preeclampsia/eclampsia, early onset preeclampsia.	in third trimester of pregnancy, and early postpartum period

Secondary Outcome Measures

Name	Time	Method
Maternal and fetal complications	Systolic and Diastolic function

Locations (1): JIPMER
🇮🇳
Pondicherry, PONDICHERRY, India
JIPMER
🇮🇳Pondicherry, PONDICHERRY, India
Nivedita
Principal investigator
09487581663
dr.niveditajha@gmail.com